Innovative Strategies in TGF-β Therapy: Selective Targeting, Synergistic Combinations, and Cutting-Edge Modalities
Time: 3:30 pm
day: Conference Day Two
Details:
- Demonstrating the use of bispecific antibodies and small molecule inhibitors to selectively block TGF-β oriented targets, reducing off-target effects and improving therapeutic outcomes
- Spotlighting the synergy between TGF-β inhibitors and immune checkpoint inhibitors in combination therapies to boost anti-tumor immunity, reduce systemic toxicity, and achieve superior clinical results in cancer and non-cancer therapy
- Highlighting the integration of TGF-β therapies with innovative modalities including RNAbased therapies and TGF-β armored cell therapies to enhance therapeutic precision, efficacy, and specificity
